Pharmaceutical company fines run into the billions of dollars and rest on public acts of justice. The most emblematic, concluded with the U.S. Department of Justice (DOJ), include GlaxoSmithKline (around $3 billion in 2012), Pfizer (around $2.3 billion in 2009) and Johnson & Johnson (around $2.2 billion in 2013). These amounts sanction illegal marketing practices, not the therapeutic value of the medicines concerned.
Definition: a pharmaceutical "settlement" is a transactional agreement, often accompanied by a guilty plea, by which a company ends civil and/or criminal proceedings by paying a sum to the public treasury, under the supervision of a judge. The amount is therefore a recorded matter of law, not a journalistic estimate.
Three cases structure the documented tally, all concluded with the DOJ and all centred on the same offence: "off-label" promotion, that is, the active marketing of a medicine for uses the FDA has not approved.
The common thread is not incidental: three distinct companies, three multi-billion settlements within a few years, the same core accusation. It is the manner of selling that was condemned, not the existence of the molecules.
Beyond the trio, other settlements complete the documented tally, with different legal configurations.
Vioxx (rofecoxib) had moreover been voluntarily withdrawn from the global market as early as September 2004, after the APPROVe trial showed an increase in long-term cardiovascular risk.
DOCUMENTED FACT. On 22 November 2011, the U.S. Department of Justice (press release 11-1524) announced that Merck Sharp & Dohme agreed to pay $950 million to resolve criminal charges and civil claims over its promotion of Vioxx (rofecoxib). The breakdown is precise: a $321,636,000 criminal fine and $628,364,000 in civil settlement.
DOCUMENTED FACT. Criminally, Merck pleaded guilty to a misdemeanor: a violation of the Food, Drug and Cosmetic Act for introducing a misbranded drug into commerce, by promoting Vioxx for rheumatoid arthritis before FDA approval. The FDA approved Vioxx for three indications in May 1999, but did not approve rheumatoid arthritis until April 2002; in between, Merck received an FDA warning letter in September 2001.
The civil part ($628.364M) covers broader allegations: off-label marketing and "inaccurate, unsupported or misleading" statements about Vioxx's cardiovascular safety. Of that civil total, $426,389,000 goes to the federal government and $201,975,000 to participating Medicaid states. Merck also signed a corporate integrity agreement with HHS-OIG.
WHAT THIS SETTLEMENT DOES NOT PROVE. A misbranding guilty plea and a civil agreement are not a court finding of a specific number of Vioxx-attributable deaths. The civil part resolves allegations without admission of liability beyond the pleaded misdemeanor. It sanctions a promotional and disclosure fault, not a judicial tally of the drug's health harms.
The tally is not limited to the United States. The European Commission sanctions a different type of offence: "pay-for-delay" agreements, by which an originator company pays a generics manufacturer to delay the arrival of a cheaper version of a medicine. These are competition fines, distinct from the American marketing frauds.
The announced amounts vary depending on the sources and on what is added up: criminal component, civil component, federal fines and settlements with the states, interest, costs. The word "around" signals this caution. A rounded and honest figure is worth more than false precision.
Another precaution is needed: adding up these sums to produce a spectacular total would be misleading. The amount of a settlement also reflects the size of the market concerned, the scale of the public programmes harmed (Medicare, Medicaid) and the particular vigour of American public action. The robust fact is not the aggregated total, it is the dated and recognised existence of each offence.
Reading this documented tally honestly also means knowing what it does not prove. These fines sanction commercial practices and judicially established failings. They say nothing about the effectiveness of the medicines, and above all: they validate no anti-vaccine theory nor any rejection of treatments.
Risperdal, Bextra, Paxil, OxyContin had legitimate indications. What was judged criminal was the lie about the risks, the withholding of data and the promotion of unapproved uses, not the principle of treating. Denouncing documented fraud and defending evidence-based medicine are not contradictory: it is exactly the same demand for truth.
What is the biggest fine against a pharmaceutical company? Among the most cited settlements, that of GlaxoSmithKline in 2012, around $3 billion, was presented by the DOJ as the largest health care fraud settled to that date in the United States. Merck's civil Vioxx settlement (2007) reached, for its part, around $4.85 billion, but without any admission of fault in that framework.
Do these fines prove the medicines are dangerous? No. They sanction marketing frauds and information failings, not the therapeutic value of the molecules. Confusing the two would lead to disinformation, and in particular to anti-vaccine conclusions that these facts in no way support.
Where can these amounts be checked? In the official press releases of the U.S. Department of Justice (justice.gov), the European Commission's competition press releases, and FDA documents, all public archives.
What is the exact amount of the Merck Vioxx fine in 2011? $950 million in total, announced by the DOJ on 22 November 2011: $321.636 million criminal fine (guilty plea for misbranding) and $628.364 million civil (of which $426.389M for the federal government and $201.975M for Medicaid states). Source: DOJ press release No. 11-1524.
This documented tally is only an entry point. To understand the full mechanism, from the major settlements to off-label marketing and regulatory capture, read our dossier "Big Pharma: convictions and fines," and dive into the mini-investigation "Big Pharma — Documented Corruption" of the L'Appel de l'Éveil collection.
Among the most cited settlements, that of GlaxoSmithKline in 2012, around $3 billion, was presented by the DOJ as the largest health care fraud settled to that date in the United States. Merck's civil Vioxx settlement (2007) reached, for its part, around $4.85 billion, but without any admission of fault in that framework.
No. They sanction marketing frauds and information failings, not the therapeutic value of the molecules. Confusing the two would lead to disinformation, and in particular to anti-vaccine conclusions that these facts in no way support.
In the official press releases of the U.S. Department of Justice (justice.gov), the European Commission's competition press releases, and FDA documents, all public archives.
$950 million in total, announced by the DOJ on 22 November 2011: $321.636 million criminal fine (guilty plea for misbranding) and $628.364 million civil (of which $426.389M for the federal government and $201.975M for Medicaid states). Source: DOJ press release No. 11-1524.
Dossier : Big Pharma & souveraineté alimentaire
MINI15: Big Pharma — La Corruption Documentée
Accueil · Collection · Journal · Dossiers · Sources